骨科指南

订阅

MedSci主页 / 所有栏目 / 骨科指南

2020 SFR建议：膝关节骨关节炎的药物治疗

2020-09-12 法国风湿病学学会 Joint Bone Spine . 2020 Sep 12;

骨关节炎

2020年9月，法国风湿病学学会(SFR)发布了膝关节骨关节炎的药物治疗建议。该建议共确立了5条一般推荐原则，6条口服药物治疗建议以及2条局部药物治疗建议，3条关节腔内治疗建议。

中文标题：

2020 SFR建议：膝关节骨关节炎的药物治疗

英文标题：

Recommendations of the French Society of Rheumatology on pharmacological treatment of knee osteoarthritis

发布机构：

法国风湿病学学会

发布日期：

2020-09-12

简要介绍：

2020年9月，法国风湿病学学会(SFR)发布了膝关节骨关节炎的药物治疗建议。该建议共确立了5条一般推荐原则，6条口服药物治疗建议以及2条局部药物治疗建议，3条关节腔内治疗建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 SFR建议：膝关节骨关节炎的药物治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=5b1941c0019e95fe, title=2020 SFR建议：膝关节骨关节炎的药物治疗, enTitle=Recommendations of the French Society of Rheumatology on pharmacological treatment of knee osteoarthritis, guiderFrom=Joint Bone Spine . 2020 Sep 12;, authorId=0, author=, summary=2020年9月，法国风湿病学学会(SFR)发布了膝关节骨关节炎的药物治疗建议。该建议共确立了5条一般推荐原则，6条口服药物治疗建议以及2条局部药物治疗建议，3条关节腔内治疗建议。, cover=https://img.medsci.cn/2020929/1601309613201_2020535.jpg, journalId=0, articlesId=null, associationId=1637, associationName=法国风湿病学学会, associationIntro=, copyright=0, guiderPublishedTime=Sat Sep 12 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年9月，法国风湿病学学会(SFR)发布了膝关节骨关节炎的药物治疗建议。该建议共确立了5条一般推荐原则，6条口服药物治疗建议以及2条局部药物治疗建议，3条关节腔内治疗建议。</p> </div> </div> </div>, tagList=[TagDto(tagId=210, tagName=骨关节炎)], categoryList=[CategoryDto(categoryId=10, categoryName=骨科, tenant=100), CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=210, guiderKeyword=骨关节炎, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5913, appHits=456, showAppHits=0, pcHits=1089, showPcHits=5450, likes=4, shares=24, comments=23, approvalStatus=1, publishedTime=Tue Sep 29 00:24:45 CST 2020, publishedTimeString=2020-09-12, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Sep 29 00:13:45 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 22:03:08 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 SFR建议：膝关节骨关节炎的药物治疗.pdf)])
2020 SFR建议：膝关节骨关节炎的药物治疗.pdf
下载请点击：
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1184114, encodeId=4d8e11841144b, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Fri Jan 14 07:24:18 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051890, encodeId=c16f105189037, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:37:52 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007125, encodeId=1553100e1255a, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a64c5228491, createdName=147961d7m33暂无昵称, createdTime=Wed Aug 11 23:06:38 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998522, encodeId=eb2e99852265, content=受教了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b9f5411347, createdName=ms8000000935322790, createdTime=Sun Jul 11 17:05:52 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976592, encodeId=ba359e6592a2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/0922a5df24904e4f86d563d49079aa1d/bf4a0e7be5fb4e7892ff94a8306fe9b7.jpg, createdBy=fc9b4705948, createdName=麻无赦, createdTime=Thu Jun 24 19:57:33 CST 2021, time=2021-06-24, status=1, ipAttribution=)]
    2022-01-14 胡国宏

    #学习#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1184114, encodeId=4d8e11841144b, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Fri Jan 14 07:24:18 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051890, encodeId=c16f105189037, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:37:52 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007125, encodeId=1553100e1255a, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a64c5228491, createdName=147961d7m33暂无昵称, createdTime=Wed Aug 11 23:06:38 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998522, encodeId=eb2e99852265, content=受教了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b9f5411347, createdName=ms8000000935322790, createdTime=Sun Jul 11 17:05:52 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976592, encodeId=ba359e6592a2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/0922a5df24904e4f86d563d49079aa1d/bf4a0e7be5fb4e7892ff94a8306fe9b7.jpg, createdBy=fc9b4705948, createdName=麻无赦, createdTime=Thu Jun 24 19:57:33 CST 2021, time=2021-06-24, status=1, ipAttribution=)]
    2021-09-16 湘雅科教

    受益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1184114, encodeId=4d8e11841144b, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Fri Jan 14 07:24:18 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051890, encodeId=c16f105189037, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:37:52 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007125, encodeId=1553100e1255a, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a64c5228491, createdName=147961d7m33暂无昵称, createdTime=Wed Aug 11 23:06:38 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998522, encodeId=eb2e99852265, content=受教了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b9f5411347, createdName=ms8000000935322790, createdTime=Sun Jul 11 17:05:52 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976592, encodeId=ba359e6592a2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/0922a5df24904e4f86d563d49079aa1d/bf4a0e7be5fb4e7892ff94a8306fe9b7.jpg, createdBy=fc9b4705948, createdName=麻无赦, createdTime=Thu Jun 24 19:57:33 CST 2021, time=2021-06-24, status=1, ipAttribution=)]
    2021-08-11 147961d7m33暂无昵称

    受益了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1184114, encodeId=4d8e11841144b, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Fri Jan 14 07:24:18 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051890, encodeId=c16f105189037, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:37:52 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007125, encodeId=1553100e1255a, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a64c5228491, createdName=147961d7m33暂无昵称, createdTime=Wed Aug 11 23:06:38 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998522, encodeId=eb2e99852265, content=受教了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b9f5411347, createdName=ms8000000935322790, createdTime=Sun Jul 11 17:05:52 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976592, encodeId=ba359e6592a2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/0922a5df24904e4f86d563d49079aa1d/bf4a0e7be5fb4e7892ff94a8306fe9b7.jpg, createdBy=fc9b4705948, createdName=麻无赦, createdTime=Thu Jun 24 19:57:33 CST 2021, time=2021-06-24, status=1, ipAttribution=)]
    2021-07-11 ms8000000935322790

    受教了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1184114, encodeId=4d8e11841144b, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Fri Jan 14 07:24:18 CST 2022, time=2022-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051890, encodeId=c16f105189037, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 11:37:52 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007125, encodeId=1553100e1255a, content=受益了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a64c5228491, createdName=147961d7m33暂无昵称, createdTime=Wed Aug 11 23:06:38 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998522, encodeId=eb2e99852265, content=受教了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2b9f5411347, createdName=ms8000000935322790, createdTime=Sun Jul 11 17:05:52 CST 2021, time=2021-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976592, encodeId=ba359e6592a2, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210619/0922a5df24904e4f86d563d49079aa1d/bf4a0e7be5fb4e7892ff94a8306fe9b7.jpg, createdBy=fc9b4705948, createdName=麻无赦, createdTime=Thu Jun 24 19:57:33 CST 2021, time=2021-06-24, status=1, ipAttribution=)]
    2021-06-24 麻无赦

    学习

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2020 AAOS循证临床实践指南：肩关节骨关节炎的管理

美国骨科医师学会(AAOS,American Academy of Orthopaedic Surgeons) · 2020-03-23

骨关节炎慢性病管理专家建议

中国风湿免疫科相关专家小组（统称） · 2020-04-30

2019 ACR/AF指南：手、髋和膝关节骨关节炎的管理

美国风湿病学会(ACR,American College of Rheumatology) · 2020-01-25

《骨关节炎诊疗指南（2018年版）》膝关节骨关节炎部分的更新与解读

暂未更新 · 2019-09-30

2019 ESCEO专家共识：肠道菌群和骨关节炎管理

欧洲骨质疏松和骨关节炎临床经济学会(ESCEO,The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) · 2019-08-19

2018 EULAR建议：炎性关节炎与骨关节炎患者的体力活动

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2018-07-11

拓展阅读

2010NHMRC 澳大利亚骨关节炎诊治

澳大利亚国家健康与医学研究理事会(NHMRC,Australian Government National Health and Medical Research Council) · 2010-01-01

2010 骨关节炎诊断及治疗指南

中华医学会风湿病学分会(CRA,Chinese Rheumatology Association) · 2010-06-01

2012 ACR 关于手部、髋部和膝部骨关节炎的非药物和药物治疗的建议

美国风湿病学会(ACR,American College of Rheumatology) · 2012-04-01

玻璃酸钠在骨关节炎治疗中的应用专家共识（2012年版）

暂未更新 · 2012-11-20

2012 《骨关节炎的康复治疗》专家共识

中国骨科相关专家小组（统称） · 2012-12-01

2013 EULAR推荐建议：髋关节和膝关节骨关节炎的非药物治疗

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2013-04-17